111 W. Cooperative Way, Building 3
About DisperSol TechnologiesDisperSol Technologies was founded in 2007 and evolved from a research collaboration with the College of Pharmacy at The University of Texas at Austin. The focus of this collaboration was to adapt and apply a unique plastics processing technology to pharmaceutical manufacturing. KinetiSol® emerged from this research as an innovative technology for the production of drug-polymer composite systems, especially amorphous solid dispersions.
CEO: Edward Rudnic
Please click here for.
Please click here for clinical trial information.
7 articles with DisperSol Technologies
DisperSol and Catalent Collaborate to Establish KinetiSol® Technology Manufacturing Hub for DisperSol Pharmaceutical Pipeline
DisperSol Technologies and Catalent announced a strategic manufacturing collaboration to accelerate the development of multiple DisperSol pharmaceutical products.
DisperSol Technologies LLC announced that it is promoting Dave A. Miller from Vice President Research & Development to Chief Scientific Officer effective immediately.
DisperSol Technologies LLC announced that it is promoting Chris Brough from Vice President Technology to Chief Technology Officer effective immediately.
DisperSol Technologies LLC announced today that its Board of Directors has appointed David S. Snyder as its Chief Financial Officer effective October 1, 2020. “David Snyder is a highly accomplished pharmaceutical finance executive with extensive experience in managing the finances and growth of life science businesses,” said Dr. Edwar
DisperSol Technologies Raising $27 Million and Initiating Phase II Trials of DST-0509 in Iron Overload Disorder
DisperSol Technologies, LLC, has secured commitments for $27 million in equity financing.
The symposium will highlight partners' experiences with KinetiSol: a novel manufacturing technology for making amorphous solid dispersions of poorly water-soluble drug molecules to enhance their bioavailability & clinical effectiveness.
DisperSol Names Dr. Edward M. Rudnic As Chief Executive Officer, RCT Leads $12 Million Funding Round